Skip to content
You are now leaving to visit

Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease

Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif. , Dec. 11, 2017 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license IONIS-HTT Rx following the completion of a